Becton Dickinson announces FDA Emergency Use Authorization for new COVID-19 diagnostic for use in U.S.

Becton Dickinson, a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a new diagnostic test that will enable hospitals to screen for COVID-19 (coronavirus) on site and get results in under three hours.

The test helps fill an urgent need across the U.S. for hospitals to access an easy-to-use, rapid diagnostic test to screen patients and health care workers for COVID-19. The test will be run on the BD MAX System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. Each unit is capable of analyzing hundreds of samples per day.

“The BioGx molecular test for the BD MAX System and our recently announced serology test that can help detect current and past exposure to COVID-19 are part of BD’s approach to give health care workers choice and access to the right test for the right situation,” said Dave Hickey, president of Integrated Diagnostic Solutions for BD. “We continue to work diligently on an antigen test for our point-of-care BD Veritor System that would complete a full portfolio of COVID-19 tests.”

To see the full release, visit Becton Dickinson’s website.

Also see:

Coverage of GBC Member companies’ philanthropic responses to COVID-19

Fox 45: Sparks company working to help Maryland speed up rapid testing

Source: Becton Dickinson